



SolAeroMed Inc.
120-4838 Richard Road SW
Calgary, AB T3E 6L1 Canada

<https://www.solaeromed.com/>

SolAeroMed Shareholder Newsletter December 18, 2018

Hello SolAeroMed shareholders

2018 has seen SolAeroMed pivot in our approach to respiratory drug development. While we believe S1226 has real relevance in Asthma, COPD and other respiratory diseases, our immediate development plans now focus on Cystic Fibrosis. This change was catalyzed by business development advice, and is being realized by our collaboration with local CF clinician Dr Mark Montgomery. Mark has worked with Francis Green and our SolAeroMed team to progress a most interesting and promising clinical trial. Earlier this month, SolAeroMed management submitted a formal clinical trial application to Health Canada. SolAeroMed management expects to receive the necessary regulatory and ethical approvals and plans to start patient recruitment in early 2019.

SolAeroMed is seeking further investment to support this clinical trial. Our SolAeroMed share price is \$7.50/share (including a warrant to exercise at same price within 1 year). Of interest to Alberta based investors, SolAeroMed is a registered participant in the Alberta Investor Tax Credit (AITC) which provides an effective discount around 30%. SolAeroMed has now used up 60% of its initial \$750,000 AITC allocation, so there remains \$300,000 of eligible investment under the AITC scheme. The AITC scheme was set up by Alberta provincial government to encourage investment into qualifying Alberta based companies. Please contact SolAeroMed management for further details.

Our AGM was held on Thursday November 29, 2018. Around 20 shareholders attended the AGM in person and on the phone. The formal agenda proceeded without issue and following our AGM, SolAeroMed management provided informal updates and facilitated discussion around: rationale for our pivot from Asthma to Cystic Fibrosis; successful treatment of a severe asthma case in the Intensive Care Unit; successful treatment of asthma in a local clinic; and progress in promoting and publishing R&D around SolAeroMed drug therapies.

2019 should prove a pivotal year in SolAeroMed development. SolAeroMed will continue to develop our lead respiratory drug therapy S1226. We will keep shareholders updated on progress through our [web site](#) and shareholder newsletters.

Wishing you & yours Health and Happiness in the New Year.

John Dennis, PhD
CEO, SolAeroMed

jdennis@solaeromed.com